At a glance
| Known as | ALKS 4510 |
|---|---|
| Sponsor | Alkermes |
| Mechanism | Orexin receptor agonist |
| Stage | Phase 1 |
| Indications | Fatigue in MS · Fatigue in Parkinson's |
| Registered trials | 0 |
| Last verified | 4 Aug 2026 |
Where it stands
ALKS 4510 aims the orexin mechanism at fatigue associated with multiple sclerosis and Parkinson's disease — two conditions where debilitating fatigue is common and poorly served by existing treatments.
It sits at Phase 1 on Alkermes' own pipeline page and is not yet listed on ClinicalTrials.gov under this compound name, so there is no public trial record to read yet.
ALKS 4510 — common questions
What is ALKS 4510 for?
Fatigue associated with multiple sclerosis and Parkinson's disease, according to Alkermes' pipeline page.
Can I find the ALKS 4510 trial on ClinicalTrials.gov?
Not yet. As of the last check on 4 August 2026 it was not listed on ClinicalTrials.gov under this compound name. The only public source is Alkermes' own pipeline page.
The rest of the class
Every other orexin agonist tracked here.
oveporexton
Takeda Pharmaceutical Company · Approved · NT1
alixorexton
Alkermes plc · Phase 3 · NT1 / NT2 / IH
cleminorexton
Centessa Pharmaceuticals · Phase 3 · NT1 / NT2 / IH
E2086
Eisai Co. · Phase 2 · NT1
TAK-360
Takeda Pharmaceutical Company · Phase 2 · NT1 / NT2 / IH
ALKS 7290
Alkermes plc · Phase 1 · ADHD
BP-205
Harmony Biosciences Holdings · Phase 1 · Not yet specified
ORX142
Centessa Pharmaceuticals · Phase 1 · Neurological / Neurodegenerative
ORX489
Centessa Pharmaceuticals · Phase 1 · Neuropsychiatric
Source
This entry was last checked against its primary source on 4 Aug 2026 by Simon Stawski: https://www.alkermes.com/research-and-development/pipeline
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when ALKS 4510 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.